Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;30(8):1060-1067.
doi: 10.1089/jwh.2021.0280.

Uterine Fibroids: Assessing Unmet Needs from Bench to Bedside

Affiliations
Review

Uterine Fibroids: Assessing Unmet Needs from Bench to Bedside

Irene O Aninye et al. J Womens Health (Larchmt). 2021 Aug.

Abstract

Uterine fibroids (leiomyomas) are noncancerous growths that can have deleterious effects on the health and quality of life for millions of women. Attempts to better understand the factors that influence prevalence and disparities associated with fibroids have been made; however, significant knowledge gaps continue to persist, which hinder care for individuals living with fibroids. The Society for Women's Health Research convened an interdisciplinary Uterine Fibroids Working Group to review the current state of knowledge about uterine fibroids and recommend areas in which to prioritize efforts to address research gaps and improve diagnosis, treatment, and access to care for patients with this chronic disease. Throughout a 2-day roundtable meeting, participants discussed updates on key literature, research, clinical practice, and public health data on uterine fibroids. Overarching themes and recommendations were identified and determined by consensus agreement of the participants at the conclusion of the meeting. Systematic studies of the etiology and pathology of uterine fibroids are needed to address important knowledge gaps and unmet clinical needs regarding the multifaceted management of fibroids and their effects on overall health and quality of life. The Working Group recommends addressing key deficits within the spheres of research, clinical care, and federal policy. Immediate needs include increasing research investment, improving fibroid assessment using pelvic imaging, implementing longitudinal study designs, addressing factors that contribute to disease disparities (especially among women of color), developing fertility-friendly treatment options, expanding awareness and education beyond gynecologic specialists, and advancing personalized patient care through shared decision-making approaches.

Keywords: gynecologic condition; heavy menstrual bleeding; hysterectomy; leiomyoma; policy; reproductive health.

PubMed Disclaimer

Conflict of interest statement

Individual members of the SWHR UFWG have not been provided any compensation for their participation in the Working Group or for the development of this article. Working Group member A.A-H. has consulted for AbbVie, Inc., Bayer, MD Stem Cells, Myovant, Novartis, and ObsEva, receives grant support from the National Institute of Health for fibroid-related research (2003-present), and is an inventor on US Patent 9790562 B2. S.A. has consulted for AbbVie, Inc., Myovant, Bayer, and Eximis, and has received author royalties for UpToDate. W.H.C. has consulted for AbbVie Inc., HELP Working Group, and ObsEva, serves as a board member for American Board of Obstetrics and Gynecology, and is the Editor-in-Chief of Fertility & Sterility Science journal of the American Society for Reproductive Medicine. P.L. is an inventor on US Patent 10369110. E.E.M. has consulted for Myovant. E.M. has consulted for AbbVie, Inc. E.A.S. has consulted for AbbVie, Inc., Bayer, Myovant, and ObsEva, is an inventor on US Patent 6440445, and has received royalties from UpToDate and payments for the development of educational content from the Med Learning Group, PER, Peer View and Massachusetts Medical Society. S.V. has consulted for AbbVie, Inc., Myovant, Bayer, Hologic, and ObsEva. L.W. has consulted for AbbVie, Inc., and has received grant support on several grants (2008-present) from the National Institutes of Health and the National Science Foundation. The remaining authors have nothing to disclose.

References

    1. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: A systematic review. BJOG 2017;124:1501–1512 - PubMed
    1. Baird DD, Patchel SA, Saldana TM, et al. . Uterine fibroid incidence and growth in an ultrasound-based, prospective study of young African Americans. Am J Obstet Gynecol 2020;223:402..e1–402.e18. - PMC - PubMed
    1. Marsh EE, Al-Hendy A, Kappus D, Galitsky A, Stewart EA, Kerolous M. Burden, prevalence, and treatment of uterine fibroids: A survey of U.S. women. J Womens Health 2018;27:1359–1367 - PMC - PubMed
    1. Ghant MS, Sengoba KS, Recht H, Cameron KA, Lawson AK, Marsh EE. Beyond the physical: A qualitative assessment of the burden of symptomatic uterine fibroids on women's emotional and psychosocial health. J Psychosom Res 2015;78:499–503 - PubMed
    1. Ghant MS, Sengoba KS, Vogelzang R, Lawson AK, Marsh EE. An altered perception of normal: Understanding causes for treatment delay in women with symptomatic uterine fibroids. J Womens Health 2016;25:846–852 - PMC - PubMed

Publication types